Phase 1b/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with FOLFIRI plus /- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

被引：28
|
作者：
Bendel, Johanna C.
Hubbard, Joleen Marie
O'Neil, Bert H.
Jonker, Derek J.
Starodub, Alexander
Peyton, James D.
Pitot, Henry C.
Halfdanarson, Thorvardur Ragnar
Nadeau, Benjamin Rolland
Zubkus, John D.
Adesunloye, Bamidele
Edenfield, William Jeffery
Li, Youzhi
Li, Wei
Grothey, Axel
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3529
引用
收藏
页数：5
相关论文
共 50 条
  • [31] First line polichemotherapy (PCT) with irinotecan plus leucovorin plus 5-fluorouracil (FOLFIRI) and bevacizumab in patients (Pts) with metastatic colorectal cancer (MCRC): A phase II study in our institution
    Roda, G.
    Nonnis, D. Carta A.
    Galmozzi, A.
    Nastasi, G.
    Cotroneo, G.
    ANNALS OF ONCOLOGY, 2007, 18 : 8 - 8
  • [32] CCL2 polymorphism as a predictive marker for bevacizumab (Bev) hi combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts)
    Siamak, Saadat
    Sunakawa, Yu
    Loupakis, Fotios
    Yang, Dongyun
    Zhang, Wu
    Ning, Yan
    Stintzing, Sebastian
    Stremitzer, Stefan
    Seblo, Ana
    Yamauchi, Shinichi
    Matsusaka, Satoshi
    El-Khoueiry, Rita Elie
    Antoniotti, Carlotta
    Rossini, Daniele
    Cremolini, Chiara
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [35] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
    Guan, Z.
    Xu, J.
    Luo, R.
    Feng, F.
    Wang, L.
    Shen, L.
    Yu, S.
    Ba, Y.
    Liang, J.
    Wang, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
    Bekaii-Saab, T.
    Starodub, A.
    El-Rayes, B.
    O'Neil, B.
    Shahda, S.
    Ciombor, K.
    Noonan, A.
    Hanna, W.
    Sehdev, A.
    Shaib, W.
    Mikhail, S.
    Neki, A.
    Oh, C.
    Li, Y. Z.
    Li, W.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).
    Nixon, Andrew B.
    Sibley, Alexander
    Hatch, Ace Joseph
    Liu, Yingmiao
    Jiang, Chen
    Mulkey, Flora
    Starr, Mark D.
    Brady, John C.
    Niedzwiecki, Donna
    Innocenti, Federico
    Venook, Alan P.
    Hochster, Howard S.
    Lenz, Heinz-Josef
    O'Neil, Bert H.
    Owzar, Kouros
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI plus bevacizumab: The GENIC study.
    Williams, Grant Richard
    Innocenti, Federico
    Wood, William Allen
    Patel, Jai Narendra
    Sherrill, Gary Bradley
    O'Neil, Bert H.
    Boles, Jeremiah C.
    Basch, Ethan M.
    Sanoff, Hanna Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
    Altomare, I.
    Russell, K. B.
    Uronis, H. E.
    Morse, M.
    Hsu, S. D.
    Zafar, Y.
    Bendell, J. C.
    Starodub, A.
    Honeycutt, W.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345